Issue 15 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Sharpless: Expect a big boost to NCI's RPG pool

Whistleblower suit claims McKesson repackaged, sold cancer drug “overfill”

Sales Revenues at the Potential Expense of Patient Safety:
The Example of You&i

In Brief

Gradishar named chief of hematology and Oncology at Northwestern

Cole named chief of pediatric hematology/oncology at Rutgers

ACS CAN report examines patient barriers to cancer clinical trial enrollment

Woodcock, Shaw and Conway-Welch receive awards from Society for Women's Health Research

Billings appointed chief medical officer at Natera

Funding Opportunities

DOD Ovarian Cancer Research Program Publishes funding opportunities

Clinical Roundup

NCI study revises molecular classification for most common type of lymphoma

Updated ASTRO guideline for lung radiation recommends concurrent chemotherapy for some stage III patients

Keytruda monotherapy meets OS endpoint in phase III trial

Epacadostat plus Keytruda don't meet PFS endpoint in phase III study in metastatic melanoma

Roswell Park, Ohio State researchers identify genes linked to blood and marrow transplant outcomes

Drugs & Targets

Rucaparib approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

FDA finalizes guidances to accelerate development of Next Gen sequencing

Karyopharm's Selinexor receive FDA Fast Track designation

MD Anderson, Nanobiotix to collaborate on preclinical research combining NBTXR3, nivolumab

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login